



AlloSeq Assign IMGT/HLA 3.53.0 Reference File Release Notes

For use with AlloSeq Tx 17 and AlloSeq Tx 9 typing kits

TEC913

Software version number: 1.0.3 +

Document Version No: 1.0

Issue Date: October 2023



ASA1.0



CareDx Pty Ltd,
20 Collie Street,
Fremantle, WA 6160,
Australia



©2023 CareDx, Inc. All service marks or trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved.

Table of Contents

1.	AlloSeq Assign Reference 3.53.0.0 for AlloSeq Tx 17 and AlloSeq Tx 9 Version Changes	3
2.	IMGT/HLA 3.53.0 Reference Update	3
3.	AlloSeq Tx Gene Coverage	3
4.	AlloSeq Tx Depth of Coverage	3
5.	Regions Included in the Core Analysis	4
6.	Base Positions Masked for Variant Calling	8
7.	Base Positions Excluded from The Phasing Calculation	9
8.	Sequence Motifs Reported	9
9.	3.53.0 CIWD List Update	10
10.	Reference Compatibility	10
11.	Reference Update Instructions	10
12.	Assign Matching Validation	10
13.	NMDP Nulls	12
14.	Customer Support	12
	Revision History	13

1. AlloSeq Assign Reference 3.53.0.0 for AlloSeq Tx 17 and AlloSeq Tx 9 Version Changes

Changes since AlloSeq Assign Reference 3.51.0.1:

1. Updated alleles as per IMGT release 3.53.0.
2. Made improvements to pseudogene references to reduce mis-mapping to targeted genes.
 - a. Added UTR sequences to DPB2 alignment sequences. Updated the alleles to include all sequences available in IMGT database.
 - b. Reviewed DQA2 reference and removed non-IMGT alleles.
 - c. Extended the alignment sequences for DRB2 at the 3'UTR. Added IMGT sequence for DRB2*01:01 and putative sequences for 2 additional DRB2 alleles.
 - d. Extended the alignment sequences for DRB8 to include more sequence for intron 2. Added IMGT sequence for DRB8*01:01.
3. Expanded the alignment sequences for HLA-G to include the 14bp indel in the 3'UTR.
 - a. Added extended sequences for 8 alleles to facilitate the alignment in the 3'UTR. These sequences are used for alignment purposes only and will not report as genotypes.
 - b. Note that there is no impact to saved projects analysed with previous reference versions due to the change to the alignment sequences as the added sequence is 3' of the IMGT reference sequences.
 - c. Added the 14bp indel as a motif. See Table 8 for more details.

2. IMGT/HLA 3.53.0 Reference Update

All alleles were validated for consistency with the IMGT/HLA ^{1,2}release database version included in the IMGT/HLA release notes, which can be found with these links:

https://www.ebi.ac.uk/ipd/imgt/hla/docs/version_r3520.html

https://www.ebi.ac.uk/ipd/imgt/hla/docs/version_r3530.html

3. AlloSeq Tx Gene Coverage

Consensus sequences have been extended beyond the regions described by IMGT. The sequences used to extend the consensus sequences have been derived from GRCh38³

4. AlloSeq Tx Depth of Coverage

The minimum depth of coverage threshold has been individually set for each locus and may vary depending upon the kit used. Positions below the minimum depth value will be starred out in the sample consensus sequence, base call quality indicated as red and excluded from the analysis.

Locus	Minimum depth (#reads)
A	30
B	30
C	30
DPA1	30
DPB1	30

¹ Robinson J, Malik A, Parham P, Bodmer JG, Marsh SGE: IMGT/HLA - a sequence database for the human major histocompatibility complex Tissue Antigens (2000), 55:280-287

² Robinson J, Barker DJ, Georgiou X, Cooper MA, Flicek P, Marsh SGE: IPD-IMGT/HLA Database. Nucleic Acids Research (2020), 48:D948-55

³ Schneider, V.A. et al. Evaluation of GRCh38 and de novo haploid genome assemblies demonstrates the enduring quality of the reference assembly. *Genome Res.* 2017 May;27(5):849-864

DQA1	30
DQB1	30
DRB1	30
DRB3	30
DRB4	30
DRB5	30
E	30
F	30
G	30
H	30
MICA	30
MICB	30

Table 1. Minimum depth of coverage

5. Regions Included in the Core Analysis

Core layer includes:

- All sequence in Exons 2, 3 and 4 of HLA Class 1, MICA and MICB and exon 2 and 3 of HLA class 2.
- Full sequence of additional exons if these exons include polymorphisms that impact expression.
- Specific non-coding positions that have sequence polymorphisms that impact expression.
- Splice sites as predicted by fruitfly and NetGene2.

Locus	Region	Position	Known Alleles with impacted expression
A	Exon 1, 2, 3, 4, 5, 6, 7, 8	all	N/A
	UTR	764	A*02:01:01:02L
	Exon 1 splice site	863-864	None
	Exon 1 donor site	938-939	A*33:03:01:21Q, A*26:01:01:52Q
	Intron 1	1042	A*31:01:02:03N
	Exon 2 acceptor site	1066-1067	None
	Exon 2 donor site	1338-1339	A*02:01:01:134Q, A*24:447Q
	Intron 2	1342-1345	A*01:01:01:02N
	Intron 2	1572	A*01:301Q, A*24:450Q, A*24:02:01:02L
	Exon 3 acceptor site	1577-1578	None
	Exon 3 donor site	1855-1856	None
	Exon 4 acceptor site	2432-2433	None
	Exon 4 donor site	2710-2711	A*03:01:01:02N, A*26:01:01:03N, A*29:01:01:02N
	Exon 5 acceptor site	2810-2811	None
	Exon 5 donor site	2929-2930	A*31:01:02:51Q
	Exon 6 acceptor site	3369-3370	None
	Exon 6 donor site	3404-3405	None
	Intron 7	3542	A*24:02:01:02L
	Exon 7 acceptor site	3544-3545	None
	Exon 7 donor site	3594-3595	A*31:01:02:30Q
	Exon 8 acceptor site	3761-3762	A*24:02:01:17Q
B	Exon 1, 2, 3, 4, 5, 6, 7	all	N/A
	UTR	691	B*39:01:01:02L
	Exon 1 splice site	841-842	None
	Exon 1 donor site	916-917	None
	Exon 2 acceptor site	1043-1044	B*15:01:01:39Q
	Intron 1	1019	B*15:01:01:02N
	Exon 2 donor site	1315-1316	B*38:01:01:03Q, B*15:616Q
	Exon 3 acceptor site	1559-1560	B*18:01:01:42Q, B*27:05:02:04Q, B*18:01:01:12Q
	Exon 3 donor site	1837-1838	B*44:02:01:13Q, B*15:01:01:65Q
	Exon 4 acceptor site	2410-2411	B*14:02:01:25Q
	Exon 4 donor site	2691-2692	B*40:02:01:32Q, B*08:284Q
	Exon 5 acceptor site	2790-2791	None
	Exon 5 donor site	2909-2910	B*44:02:01:02S, B*56:01:01:05S
	Exon 6 acceptor site	3348-3349	None
	Exon 6 donor site	3383-3384	None

Locus	Region	Position	Known Alleles with impacted expression
C	Exon 7 acceptor site	3487-3488	B*51:01:01:97Q
	Exon 7 donor site	3537-3538	none
	Exon 1, 2, 3, 4, 5, 7, 8	All	N/A
	Exon 1 splice site	931-932	None
	Exon 1 donor site	1006-1007	C*15:02:01:30Q
	Exon 2 acceptor site	1134-1135	C*05:01:01:53Q, C*07:01:01:14Q, C*03:03:01:52N, C*07:04:01:16Q
	Exon 2 donor site	1406-1407	C*15:02:01:35Q
	Exon 3 acceptor site	1655-1656	C*03:03:01:50N, C*15:02:01:08N, C*07:01:01:100Q, C*07:04:01:15Q, C*17:01:01:16Q, C*02:02:02:74Q, C*03:03:01:55Q, C*04:01:01:170Q, C*05:01:01:80Q, C*07:02:01:137Q, C*07:01:01:127Q
	Exon 3 donor site	1933-1934	C*02:02:02:34Q, C*03:04:01:35Q, C*07:02:01:17N, C*07:02:01:125Q, C*03:03:01:39Q
	Exon 4 acceptor site	2518-2519	None
	Exon 4 donor site	2796-2797	C*04:01:01:47Q
	Exon 5 acceptor site	2915-2916	None
	Exon 5 donor site	3037-3038	None
	Exon 6 acceptor site	3477-3478	C*07:06:01:05Q, C*04:01:01:84Q
	Exon 6 donor site	3512-3513	None
	Exon 7 acceptor site	3617-3618	C*07:0201:124Q
	Exon 7 donor site	3667-3668	C*07:02:01:74Q
	Exon 8 acceptor site	3829-3830	None
DPA1	Exon 1, 2, 3, 4	All	N/A
	Exon 1 splice site	1429-1430	None
	Exon 1 donor site	1531-1532	DPA1*01:03:01:18Q
	Exon 2 acceptor site	5113-5114	None
	Exon 2 donor site	5361-5362	None
	Exon 3 acceptor site	5699-5700	None
	Exon 3 donor site	5983-5984	None
	Exon 4 acceptor site	6195-6196	None
	Exon 4 donor site	6352-6353	None
DPB1	Exon 1, 2, 3, 4	All	N/A
	Exon 1 splice site	1037-1038	None
	Exon 1 donor site	1143-1144	None
	Exon 2 acceptor site	5677-5678	None
	Exon 2 donor site	5943-5944	DPB1*04:01:01:24N
	Exon 3 acceptor site	9955-9956	None
	Exon 3 donor site	10239-10240	None
	Exon 4 acceptor site	10784-10785	None
	Exon 4 donor site	10897-10898	DPB1*02:01:02:46Q
	Exon 5 acceptor site	11224-11225	None
	Exon 5 donor site	11249-11250	None
DQA1	Exon 1, 2, 3, 4	All	N/A
	Exon 1 splice site	1458-1459	None
	Exon 1 donor site	1542-1543	None
	Exon 2 acceptor site	5396-5397	None
	Exon 2 donor site	5647-5648	None
	Exon 3 acceptor site	6038-6039	None
	Exon 3 donor site	6322-6323	None
	Exon 4 acceptor site	6683-6684	DQA1*03:03:01:16Q
	Exon 4 donor site	6840-6841	None
DQB1	Exon 1, 2, 3, 4	All	N/A
	Exon 1 splice site	689-690	None
	Exon 1 donor site	800-801	None
	Exon 2 acceptor site	2269-2270	None
	Exon 2 donor site	2541-2542	None
	Exon 3 acceptor site	5585-5586	None
	Exon 3 donor site	5869-5870	DQB1*03:01:01:21N, DQB1*04:02:01:16Q
	Exon 4 acceptor site	6384-6385	DQB1*02:01:01:16Q
	Exon 4 donor site	6497-6498	None
	Exon 5 acceptor site	6980-6981	None
	Exon 5 donor site	7006-7007	None
	Exon 6 acceptor site	7615-7616	None
	Exon 6 donor site	7631-7632	None
DRB1G01	Exon 2, 3, 6	All	N/A
	Exon 1 splice site	1204-1205	None
	Exon 1 donor site	1306-1307	None
	Exon 2 acceptor site	6593-6594	None
	Exon 2 donor site	6865-6866	None

Locus	Region	Position	Known Alleles with impacted expression
	Exon 3 acceptor site	9148-9149	None
	Exon 3 donor site	9432-9433	None
	Exon 4 acceptor site	10131-10132	None
	Exon 4 donor site	10244-10245	None
	Exon 5 acceptor site	10729-10730	None
	Exon 5 donor site	10755-10756	None
	Exon 6 acceptor site	10897-10898	None
	Exon 6 donor site	11913-11914	None
DRB1G03	Exon 2, 3, 6	All	N/A
	Exon 1 acceptor site	1199-1200	None
	Exon 1 donor site	1302-1303	None
	Exon 2 acceptor site	9305-9306	None
	Exon 2 donor site	9577-9578	None
	Exon 3 acceptor site	11834-11835	None
	Exon 3 donor site	12118-12119	DRB1*11:01:01:12Q
	Exon 4 acceptor site	12817-12818	None
	Exon 4 donor site	12930-12931	None
	Exon 5 acceptor site	13400-13401	None
DRB1G04	Exon 5 donor site	13426-13427	None
	Exon 6 acceptor site	14213-14214	None
	Exon 2, 3, 6	All	N/A
	Exon 1 acceptor site	1199-1200	None
	Exon 1 donor site	1301-1302	None
	Exon 2 acceptor site	9554-9555	None
	Exon 2 donor site	9826-9827	None
	Exon 3 acceptor site	13288-13289	None
	Exon 3 donor site	13572-13573	None
	Exon 4 acceptor site	14267-14268	None
DRB1G07	Exon 4 donor site	14380-14381	None
	Exon 5 acceptor site	14850-14851	None
	Exon 5 donor site	14876-14877	None
	Exon 6 acceptor site	15502-15503	None
	Exon 2, 3, 6	All	N/A
	Exon 1 acceptor site	1184-1185	None
	Exon 1 donor site	1287-1288	None
	Exon 2 acceptor site	11598-11599	None
	Exon 2 donor site	11870-11871	None
	Exon 3 acceptor site	14095-14096	None
DRB3	Exon 3 donor site	14379-14380	None
	Exon 4 acceptor site	15074-15075	None
	Exon 4 donor site	15187-15188	None
	Exon 5 acceptor site	15660-15661	None
	Exon 5 donor site	15686-15687	None
	Exon 6 acceptor site	16402-16403	None
	Exon 2, 3	All	N/A
	Exon 1 acceptor site	1199-1200	None
	Exon 1 donor site	1301-1302	None
	Exon 2 acceptor site	8972-8973	None
DRB4	Exon 2 donor site	9244-9245	None
	Exon 3 donor site	11842-11843	None
	Exon 3 donor site	11842-11843	None
	Exon 4 acceptor site	12524-12525	None
	Exon 4 donor site	12637-12638	None
	Exon 5 acceptor site	13108-13109	None
	Exon 5 donor site	13134-13135	None
	Exon 6 acceptor site	13931-13932	None
	Exon 1, 2, 3	All	N/A
	Exon 1 acceptor site	1232-1233	none
DRB5	Exon 1 donor site	1334-1335	none
	Exon 2 acceptor site	10896-10897	DRB4*01:03:01:02N, DRB4*01:14N, DRB4*01:03:01:13N
	Exon 2 donor site	11168-11169	None
	Exon 3 acceptor site	13909-13910	None
	Exon 3 donor site	14193-14194	None
	Exon 4 acceptor site	14895-14896	None
	Exon 4 donor site	15008-15009	None
	Exon 5 acceptor site	15480-15481	None
	Exon 5 donor site	15506-15507	None
	Exon 6 acceptor site	15806-15807	None
DRB5	Exon 2, 3	All	N/A
	Exon 1 acceptor site	1275-1276	None

Locus	Region	Position	Known Alleles with impacted expression
	Exon 1 donor site	1377-1378	None
	Exon 2 acceptor site	9325-9326	None
	Exon 2 donor site	9597-9598	None
	Exon 3 acceptor site	11848-11849	None
	Exon 3 donor site	12132-12133	None
	Exon 4 acceptor site	12833-12834	None
	Exon 4 donor site	12946-12947	None
	Exon 5 acceptor site	13422-13423	None
	Exon 5 donor site	13448-13449	None
	Exon 6 acceptor site	13747-13748	None
	Exon 6 donor site	13763-13764	None
E	Exon 1, 2, 3, 4	All	N/A
	Exon 1 donor site	1597-1598	None
	Exon 2 acceptor site	1725-1726	None
	Exon 2 donor site	1997-1998	None
	Exon 3 acceptor site	2239-2240	None
	Exon 3 donor site	2517-2518	None
	Exon 4 acceptor site	3136-3137	None
	Exon 4 donor site	3414-3415	None
	Exon 5 acceptor site	3536-3537	None
	Exon 5 donor site	3655-3656	None
	Exon 6 acceptor site	4403-4404	None
	Exon 6 donor site	4438-4439	None
	Exon 7 acceptor site	4540-4541	None
	Exon 7 donor site	4585-4586	None
	Exon 8 acceptor site	4748-4749	None
F	Exon 2, 3, 4	All	N/A
	Exon 1 donor site	1529-1530	None
	Exon 2 acceptor site	1657-1658	None
	Exon 2 donor site	1929-1930	None
	Exon 3 acceptor site	2172-2173	None
	Exon 3 donor site	2450-2451	None
	Exon 4 acceptor site	3030-3031	None
	Exon 4 donor site	3308-3309	None
	Exon 5 acceptor site	3446-3447	None
	Exon 5 donor site	3565-3566	None
	Exon 6 acceptor site	4010-4011	None
	Exon 6 donor site	4045-4046	None
	Exon 7 acceptor site	4402-4403	None
G	Exon 2, 3, 4	All	N/A
	Exon 1 acceptor site	1844-1845	none
	Exon 1 donor site	1919-1920	none
	Exon 2 acceptor site	2046-2047	G*01:01:01:14Q
	Exon 2 donor site	2318-2319	none
	Exon 3 acceptor site	2542-2543	none
	Exon 3 donor site	2820-2821	none
	Exon 4 acceptor site	3417-3418	G*01:01:02:05Q
	Exon 4 donor site	3695-3696	none
	Exon 5 acceptor site	3815-3816	G*01:04:01:04Q
	Exon 5 donor site	3934-3935	None
	Exon 6 acceptor site	4377-4378	None
H	Exon 2, 3, 4	All	N/A
	Exon 1 acceptor site	670-671	None
	Exon 1 donor site	745-746	None
	Exon 2 acceptor site	867-868	None
	Exon 2 donor site	1139-1140	None
	Exon 3 acceptor site	1379-1380	None
	Exon 3 donor site	1657-1658	None
	Exon 4 acceptor site	2240-2241	None
	Exon 4 donor site	2517-2518	None
	Exon 5 acceptor site	2617-2618	None
	Exon 5 donor site	2736-2737	None
	Exon 6 acceptor site	3174-3175	None
	Exon 6 donor site	3209-3210	None
	Exon 7 acceptor site	3349-3350	None
	Exon 7 donor site	3570-3571	None
MICA	Exon 2, 3, 4	All	N/A
	Exon 1 donor site	805-806	None
	Exon 2 acceptor site	7744-7745	None
	Exon 2 donor site	8001-8002	None

Locus	Region	Position	Known Alleles with impacted expression
	Exon 3 acceptor site	8273-8274	None
	Exon 3 donor site	8563-8564	None
	Exon 4 acceptor site	9148-9149	None
	Exon 4 donor site	9429-9430	MICA*002:01:13Q
	Exon 5 acceptor site	9527-9528	None
	Exon 5 donor site	9676-9677	None
	Exon 6 acceptor site	12224-12225	None
	Exon 2, 3, 4	All	N/A
	Exon 1 donor site	673-674	None
	Exon 2 acceptor site	8213-8214	None
MICB	Exon 2 donor site	8470-8471	MICA*011:01:04Q, MICA*171Q
	Exon 3 acceptor site	8739-8740	None
	Exon 3 donor site	9029-9030	None
	Exon 4 acceptor site	9618-9619	None
	Exon 4 donor site	9899-9900	None
	Exon 5 acceptor site	9996-9997	None
	Exon 5 donor site	10130-10131	None
	Exon 6 acceptor site	12378-12379	None

Table 2. Regions included in Core Analysis

6. Base Positions Masked for Variant Calling

The following base position and/or regions have been excluded from analysis due to incomplete coverage of resulting reads or commonly occurring low sequence quality.

Locus	Region
A	5'UTR 1-564, 3'UTR 4068-5012
B	5'UTR 1-558, Intron 2 1525-1527, 1532, 3'UTR 3568-3591
C	5'UTR 1-429, 3'UTR 4294, 4750-5503
DPA1	none
DPB1	none
DQA1	5'UTR 1-507, 1090-1135, Intron 1 2656-4926, Intron 3 6434-6442, UTR 7215-9067
DQB1	5'UTR 1-159, Intron 1 1500-1954, Intron 2 2844-5344, UTR 7837-9867
DRB1G01	5'UTR 1-606, Intron 1 1389-6100, Intron 2 6947-8624, Intron 5 10803-11597, 3'UTR 12000-13004
DRB1G03	5'UTR 1-354, Intron 1 2003-8490, Intron 2 9656-11255, Intron 5 14073-14179, 3'UTR 14239-15315
DRB1G04	5'UTR 1-321, Intron 1 2077-8889, Intron 2 9907-12648, 3'UTR 15762-16609
DRB1G07	5'UTR 1-489, Intron 1 2055-10875, Intron 2 11924-13924, Intron 5 16003-16129, 3'UTR 16741-17509
DRB3	5'UTR 1-596, Intron 1 2140-8211, Intron 2 9310-9386, 10050-10929, Intron 3 12049-12050, 3'UTR 14449-15285
DRB4	5'UTR 1-552, Intron 1 2143-10115, Intron 2 11241-11274, 11705-13267, 3'UTR 16556-17569
DRB5	5'UTR 1-351, Intron 1 2175-8498, Intron 2 9678-9702, 10077-11334, 3'UTR 14648-15558
E	5'UTR 1-1232, Intron 5 3975-3976, 3'UTR 5505-8002
F	5'UTR 1-1164, 3'UTR 4561-4586, 4715-5140
G	5'UTR 1-1545, 3'UTR 4684-6503
H	5'UTR 1-371, 3'UTR 3870-4798
MICA	Intron 1 1642-7126, Intron 5 10391-11253 / non-coding regions excluded from analysis
MICB	Intron 1 820-1246, 1435-7555, Intron 5 11136-11422 / non-coding regions excluded from analysis

Table 3. Regions masked per locus

7. Base Positions Excluded from The Phasing Calculation

The following base positions have been identified to potentially result in inappropriate phasing and have been excluded from the phasing calculation.

Locus	Region
HLA-A	intron 3, positions 2123-2124
HLA-H	exon 1, positions 723-728
DQB1	intron 1, position 1463
HLA-C	5'UTR position 768-770
MICA	Intron 4, position 9525

Table 4. Regions excluded from the phasing calculation per locus

8. Sequence Motifs Reported

For more details of the clinical significance of sequence motifs reports by AlloSeq Assign, refer to TEC747-S.

The following sequence motifs identified as biologically important are reported with IMGT HLA Reference 3.53.0.0:

Motif	SNP/Details	Assign location, Region, codon	References
Bw4/Bw6	Refer to IFU	Refer to IFU	Gumperz, J., Litwin, V., Phillips, J., Lanier, L. and Parham, P. (1995). The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. <i>Journal of Experimental Medicine</i> , 181(3), pp.1133-114
DPB1	rs9277534	12037, UTR	Effie W. Petersdorf. High HLA-DP Expression and Graft-versus-Host Disease. <i>The Journal of New England Medicine</i> . 2015 August. Bianca Schöne. Predicting an HLA-DPB1 expression marker based on standard DPB1 genotyping: Linkage analysis of over 32,000 samples. <i>Human Immunology</i> . 2018.
MICA 129Met/Val	rs1051792	8403, Exon 3, c.129	Antje Isernhagen. Impact of the MICA-129Met/Val Dimorphism on NKG2D-Mediated Biological Functions and Disease Risks. <i>frontiers</i> . 2016 Dec. Fuerst D. et.al. Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation. <i>Blood</i> . 2016 Dec 29;128(26):3169-3176.
MICB 98Met/Ile	rs3134900	8776, Exon 3, c.98	Kanya Klumkrathok. Allelic MHC Class I Chain Related B (MICB) Molecules Affect the Binding to the Human Cytomegalovirus (HCMV) Unique Long 16 (UL16) Protein: Implications for Immune Surveillance. <i>Journal of Microbiology</i> . 2013. Carapito R. et.al. Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status. <i>Bone Marrow Transplant</i> . 2020 Jul;55(7):1367-1378.
HLA-G +3196	rs1610696	5043, UTR	Adamson.M.B. HLA-G +3196 polymorphism as a risk factor for cell mediated rejection following heart transplant. <i>Elsevier</i> . 2020 Jan09.
HLA-B rs1050458C>T dimorphism	rs1050458	853, Exon 1, c.-21	Petersdorf.E.W. Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. <i>The Lancet</i> . 2020 Jan.
HLA-G 3'UTR 14bp indel	rs371194629	4808, UTR	La Nasa, G. The human leucocyte antigen-G 14-basepair polymorphism correlates with graft-versus-host disease in unrelated bone marrow transplantation for thalassaemia. <i>BJH</i> . 2007 May. Chen, D.P. The association between genetic variants at 3'-UTR and 5'-UTR of HLA-G gene and the clinical outcomes of patients with

Motif	SNP/Details	Assign location, Region, codon	References
			<p>leukemia receiving hematopoietic stem cell transplantation. <i>Frontiers Immunol.</i> 2023 Feb.</p> <p>Boukouaci, W. Association of HLA-G low expressor genotype with severe acute graft-versus-host disease after sibling bone marrow transplantation. <i>Frontiers Immunol.</i> 2011 Dec.</p> <p>Zhan-Kui Jin. Impact of HLA-G 14-bp polymorphism on acute rejection and cytomegalovirus infection in kidney transplant recipients from north-western China. <i>Transplant Immunology.</i> 2012 Jun.</p>

Table 5. Sequence Motifs

9. 3.53.0 CIWD List Update

All alleles in the CIWD list supplied by the Immunogenetics Data Analysis Working Group, version 3.0.0, as well as DPA1 and DQA1 alleles from version 2.0.0 are included in the AlloSeq Assign CWD list. When CIWD alleles have been split into subgroups after the most recent CIWD list, all alleles in the subgroups are included in the AlloSeq Assign CIWD list.

10.Reference Compatibility

The IMGT HLA Reference 3.53.0.0 is compatible and validated with AlloSeq Assign v1.0.3 and v1.0.4 when used in conjunction with the AlloSeq Tx 17 or AlloSeq Tx 9 assay.

11.Reference Update Instructions

1. Open AlloSeq Assign software.
2. In the Settings menu, select **Tx17 or Tx9** as applicable.
3. In the System group, select **Update**.
4. In the Update window, under Import, select **References & CWD**.
5. Browse to the IMGT HLA Reference folder. In the bottom right of the dialogue window, 'Reference Files' is indicated. Select all the files in the folder and select **Open**.
6. Browse to the CWD folder. In the bottom right of the dialogue window, "CWD Files" is indicated. Select the CIWD files and select **Open**.
The dialogue window indicates files successfully copied.
7. Select 'CIWD 2020 v3.53 cat 1' or 'CIWD 2020 v3.53 cat 1-2' as needed from the 'CWD Set' drop down list on the 'Annotation' panel.
8. Click 'Update' on the 'Settings' panel and choose 'Yes' to confirm the changes.

12.Assign Matching Validation

IMGT/HLA library version: **3.53.0**

Tested using Assign version(s):	1.0.3.1337
---------------------------------	------------

Notes:

1. Validation was performed by converting new fasta sequences available from IMGT to homozygous fastq files and importing into AlloSeq Assign. Genotyping reports were then generated and compared against the known genotype of the fasta sequence. Any discrepancies are listed in section 2 of this document.
2. Modified and corrected alleles are included in this validation.
3. * The new allele A*24:608N has a large deletion beginning in intron 3 g1001 that removes exons 4-7 thus it gives a "low coverage" result in Assign.
4. **The new allele DRB5*01:131N has a large deletion of 366bps from position g8034 in intron 1 to position g8399 intron 2 thus it gives a "low coverage" result in Assign.

Outputs:	
HLA-A	
Number of New Alleles:	221
Number of New Alleles Successfully Imported:	221
Number of New alleles Successfully Reported:	220*
HLA-B	
Number of New Alleles:	273
Number of New Alleles Successfully Imported:	273
Number of New alleles Successfully Reported:	273
HLA-C	
Number of New Alleles:	282
Number of New Alleles Successfully Imported:	282
Number of New alleles Successfully Reported:	282
HLA-DPA1	
Number of New Alleles:	80
Number of New Alleles Successfully Imported:	80
Number of New alleles Successfully Reported:	80
HLA-DPB1	
Number of New Alleles:	71
Number of New Alleles Successfully Imported:	71
Number of New alleles Successfully Reported:	71
HLA-DQA1	
Number of New Alleles:	109
Number of New Alleles Successfully Imported:	109
Number of New alleles Successfully Reported:	109
HLA-DQB1	
Number of New Alleles:	53
Number of New Alleles Successfully Imported:	53
Number of New alleles Successfully Reported:	53
HLA-DRB1	
Number of New Alleles:	71
Number of New Alleles Successfully Imported:	71
Number of New alleles Successfully Reported:	71
HLA-DRB3	
Number of New Alleles:	16
Number of New Alleles Successfully Imported:	16
Number of New alleles Successfully Reported:	16
HLA-DRB4	
Number of New Alleles:	10
Number of New Alleles Successfully Imported:	10
Number of New alleles Successfully Reported:	10
HLA-DRB5	
Number of New Alleles:	7
Number of New Alleles Successfully Imported:	7
Number of New alleles Successfully Reported:	6**
HLA-E	
Number of New Alleles:	1
Number of New Alleles Successfully Imported:	1
Number of New alleles Successfully Reported:	1
HLA-F	
Number of New Alleles:	1
Number of New Alleles Successfully Imported:	1
Number of New alleles Successfully Reported:	1
HLA-G	
Number of New Alleles:	4
Number of New Alleles Successfully Imported:	4
Number of New alleles Successfully Reported:	4

HLA-H	
Number of New Alleles:	4
Number of New Alleles Successfully Imported:	4
Number of New alleles Successfully Reported:	4
MICA	
Number of New Alleles:	1
Number of New Alleles Successfully Imported:	1
Number of New alleles Successfully Reported:	1
MICB	
Number of New Alleles:	0
Number of New Alleles Successfully Imported:	0
Number of New alleles Successfully Reported:	0

Table 5: Validation Data for the Assign Matching Algorithm

13.NMDP Nulls

Homozygous fastq sequences were imported into AlloSeq Assign v1.0.3.1337 with the 3.53.0.0 references for null alleles requiring exclusion from the G-group as indicated in the NMDP Policy for HLA Confirmatory Typing Requirements for Unrelated Adult Donors and HLA Typing Requirement for Patients - CIWD Null Allele Exclusion Requirement Table. No allele ambiguities were identified.

HLA-A	HLA-B	HLA-C	HLA-DRB345
A*01:04N	B*15:01:01:02N	C*04:09N	DRB4*01:03:01:02N
A*02:83N	B*40:155N		DRB5*01:08N
A*03:21N	B*51:11N		
A*11:21N			
A*24:09N			
A*24:11N			
A*31:14N			

Table 6. CIWD null alleles requiring exclusion from the G-Group.

Note that due to limitations within the software it is not possible to exclude DRB4*03:01N/DRB4*01:01:01 when the sample is homozygous.

14.Customer Support

Website: <https://labproducts.caredx.com/>

For Technical Support please email: techsupport-global@caredx.com

For ordering details, please refer to the CareDx website: <https://labproducts.caredx.com/>

Legal Manufacturer:

CareDx Pty Ltd,
20 Collie Street,
Fremantle, WA 6160,
Australia



Revision History

Version	Date	Modification	Reference/Justification
1.0	02-Oct-23	Updated to include changes made in 3.53.0.0.	N/A